第 1 到 2 筆結果,共 2 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2015 | Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010 | Kuo H.-C.; HO-HSIUNG LIN ; HONG-JENG YU ; Cheng C.-L.; Hung M.-J.; Lin A.T.L.; Chang C.-H.; Chuang Y.-C.; Cha T.-L.; Chen G.-D.; Chen C.-S.; Wu M.-P.; Wu T.-L.; Yu K.-J.; Huang S.-T.; The Taiwan Mirabegron Study Team | Urological Science | 0 | 0 | |
2 | 2013 | Erratum: Anti-angiogenic effects and mechanism of prazosin (The Prostate (2011) 71 (976-984)) | Liao C.-H.; JIH-HWA GUH ; SHIH-CHIEH CHUEH ; HONG-JENG YU | Prostate | 0 | 0 |